Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice
Status:
Withdrawn
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomised, open-label, crossover, 2-period comparative phase IV
study.
The primary objective is to compare the effect of dapagliflozin 10 mg once daily in
combination with metformin at a daily dose of ≤1,500 mg vs. metformin monotherapy with dose
titrated up to 2,500 mg/day on the overall quality of life, obesity-specific quality of life
and treatment satisfaction in patients with type 2 diabetes.